SGMT Stock Forecast & Price Target

Sagimet Biosciences is supported by denifanstat’s strong 52-week acne dataset, which showed IGA success improving from about 37% to 58% with total, inflammatory, and non-inflammatory lesion reductions reaching 73%, 78%, and 68%, respectively, while efficacy continued to deepen through roughly six months. The durability across both active and placebo-crossover arms, together with a clean long-term safety profile and no treatment-related serious adverse events or permanent AE discontinuations, reduces clinical risk and strengthens confidence that the drug can be used chronically. Fundamentally, the company’s outlook is positive because denifanstat appears differentiated as a once-daily, non-antibiotic oral option that could fit between oral antibiotics and isotretinoin, supporting longer patient duration, broader market adoption, and meaningful commercial potential in acne.

Sagimet Biosciences is viewed negatively because its valuation depends on a highly speculative DCF framework using an 11.3% WACC and a 12.5x exit multiple on 2036 estimates, while the company remains exposed to meaningful clinical, regulatory, commercial, intellectual property, and financing risks. Although denifanstat in acne has encouraging Phase 3 validation, the main downside risks are reproducibility in a broader population, durability, long-term safety, and failure of TVB-3567 or other FASN assets, any of which could derail the pipeline. Financially, Sagimet is expected to continue generating net losses at least through commercialization and likely the early launch phase, and it may need additional capital that could dilute shareholders, while also facing commercialization challenges in a >5M-patient U.S. acne market against low-cost generics and a roughly $7,000 annual price point.